# Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy

Source: https://onco.cc/trials/nct07337876/  
OnCo record `nct07337876` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of MR-guided adaptive radiotherapy in Rectal cancer, run by University Hospital Tuebingen, now recruiting.

## Summary

Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy is a phase 2 interventional study registered as NCT07337876 by University Hospital Tuebingen, with 100 participants planned, started 2026-01-07 and due to reach its primary completion in 2029-01. Interventions recorded: Dose escalated radiotherapy using a 1.5 T MR-Linac. Conditions recorded: Rectal Cancer.

Linked to the technology MR-guided adaptive radiotherapy because the registry's title names it ("mr guided adaptive radiotherapy") and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07337876
- Phase: 2
- Setting: Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy
- Sponsor: University Hospital Tuebingen
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07337876: https://clinicaltrials.gov/study/NCT07337876

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/)

---
JSON: https://onco.cc/api/v1/entities/nct07337876.json